These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Pharmacodynamic profiling of intravenous antibiotics against prevalent Gram-negative organisms across the globe: the PASSPORT Program-Asia-Pacific Region. Roberts JA; Kwa A; Montakantikul P; Gomersall C; Kuti JL; Nicolau DP Int J Antimicrob Agents; 2011 Mar; 37(3):225-9. PubMed ID: 21168997 [TBL] [Abstract][Full Text] [Related]
6. [Proper use of carbapenem antibiotics based on the feature in the treatment of infectious diseases (discussion)]]. Kaku M; Inoue M; Sagawa K; Nasu M; Yokoyama T Jpn J Antibiot; 2004 Feb; 57(1):1-10. PubMed ID: 15116571 [No Abstract] [Full Text] [Related]
7. Activity of cefepime and carbapenems in experimental pneumonia caused by porin-deficient Klebsiella pneumoniae producing FOX-5 beta-lactamase. Pichardo C; del Carmen Conejo M; Bernabéu-Wittel M; Pascual A; Jiménez-Mejías ME; de Cueto M; Pachón-Ibáñez ME; García I; Pachón J; Martínez-Martínez L Clin Microbiol Infect; 2005 Jan; 11(1):31-8. PubMed ID: 15649301 [TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo antibacterial activities of meropenem, a new carbapenem antibiotic. Harabe E; Kawai Y; Kanazawa K; Otsuki M; Nishino T Drugs Exp Clin Res; 1992; 18(2):37-46. PubMed ID: 1644010 [TBL] [Abstract][Full Text] [Related]
9. Meropenem: a new carbapenem antimicrobial. Pryka RD; Haig GM Ann Pharmacother; 1994 Sep; 28(9):1045-54. PubMed ID: 7803882 [TBL] [Abstract][Full Text] [Related]
10. Antibacterial properties of meropenem towards clinical isolates, beta-lactamase producers and laboratory mutants. Wiedemann B; Zühlsdorf M J Antimicrob Chemother; 1989 Sep; 24 Suppl A():197-205. PubMed ID: 2681124 [TBL] [Abstract][Full Text] [Related]
11. [Carbapenems in pediatrics]. Aujard Y Arch Pediatr; 1996; 3 Suppl 1():298s-301s. PubMed ID: 8796048 [No Abstract] [Full Text] [Related]
12. Postantibiotic leukocyte enhancement of meropenem against gram-positive and gram-negative strains. Novelli A; Fallani S; Cassetta MI; Conti S; Mazzei T Antimicrob Agents Chemother; 2000 Nov; 44(11):3174-6. PubMed ID: 11036045 [TBL] [Abstract][Full Text] [Related]
14. [Clinical efficacy of carbapenems in the treatment of destructive pneumonia and chronic purulent bronchitis]. Sokolova VI; Shenderovich VA; Orlov VA; Smirnova LB Antibiot Khimioter; 2003; 48(10):21-4. PubMed ID: 15004976 [No Abstract] [Full Text] [Related]
15. [Preclinical evaluation of meropenem, a new parenteral carbapenem]. Edwards JR New Microbiol; 1995 Oct; 18 Suppl():19S-31S. PubMed ID: 8574929 [TBL] [Abstract][Full Text] [Related]
16. Bacteriostatic and bactericidal in-vitro activity of meropenem against clinical isolates, including Mycobacterium avium complex. Inderlied CB; Lancero MG; Young LS J Antimicrob Chemother; 1989 Sep; 24 Suppl A():85-99. PubMed ID: 2808217 [TBL] [Abstract][Full Text] [Related]
18. The pharmacology of meropenem, a new carbapenem antibiotic. Craig WA Clin Infect Dis; 1997 Feb; 24 Suppl 2():S266-75. PubMed ID: 9126702 [TBL] [Abstract][Full Text] [Related]
19. Sensitivities to four carbapenems of bacteria isolated from patients with refractory complicated urinary tract infections and the detection of carbapenemase-producing Pseudomonas aeruginosa. Matsumoto T; Kumazawa J; Nagayama A J Antimicrob Chemother; 1996 Aug; 38(2):322-4. PubMed ID: 8877553 [No Abstract] [Full Text] [Related]
20. Comparative in vitro activity of Meropenem, Imipenem and Piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study. Joly-Guillou ML; Kempf M; Cavallo JD; Chomarat M; Dubreuil L; Maugein J; Muller-Serieys C; Roussel-Delvallez M BMC Infect Dis; 2010 Mar; 10():72. PubMed ID: 20298555 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]